Neuropathy News and Research

RSS

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex Therapeutics, Inc. today announced final results from the Company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.

9 Dec 2012

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Results from the first large, global Phase III study of Halaven (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer were presented today during the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.

7 Dec 2012

Scientists identify underlying genetic cause for rare motor neurone disorder

Scientists have identified an underlying genetic cause for a rare disorder of motor neurones, and believe this may help find causes of other related diseases.

7 Dec 2012

Ultrasound applied to fingertips can stimulate sensory pathways leading to the brain

A century after the world's first ultrasonic detection device - invented in response to the sinking of the Titanic -Virginia Tech Carilion Research Institute scientists have provided the first neurophysiological evidence for something that researchers have long suspected: ultrasound applied to the periphery, such as the fingertips, can stimulate different sensory pathways leading to the brain.

7 Dec 2012

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

DARA BioSciences, Inc., a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today it has submitted an Orphan Drug Application to the U.S. Food and Drug Administration (FDA) for KRN5500, a compound in development to treat a painful form of chronic chemotherapy-induced peripheral neuropathy (CCIPN).

30 Nov 2012

FDA clears NeuroMetrix’s SENSUS Pain Management System

NeuroMetrix, Inc., a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, reported that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the disposable electrode that is used in conjunction with its SENSUS device.

30 Nov 2012

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring key sets of VIMPAT® (lacosamide) C-V data at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, Calif., November 30 - December 4.

29 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Ankle repair recovery predictors identified

Findings from a cohort study point to factors that may influence the outcome of patients with ankle fractures requiring surgery.

22 Nov 2012

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).

20 Nov 2012

New €6 million European project to address complications associated with diabetes

NUI Galway has been awarded a major new €6 million European project, designed to address complications associated with diabetes. The research project will examine the ability of stem cells to safely control glucose levels and alleviate the damage caused by six different diabetic complications.

19 Nov 2012

Adding bortezomib ‘boosts acute myeloid leukemia chemotherapy response’

Older patients with untreated acute myeloid leukemia may benefit from having bortezomib added to daunorubicin and cytarabine during induction therapy and to consolidation intermediate-dose cytarabine, the results of a US study indicate.

14 Nov 2012

Diabetic foot complication risk highlighted in men

Men should be considered for aggressive treatment for foot complications associated with diabetes, such as ulceration and amputation, say researchers.

8 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Nabilone shows promise in treating diabetic neuropathy

A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

31 Oct 2012

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

23 Oct 2012

Linezolid proves effective in treating drug-resistant TB

When tested in patients hospitalized with extensively drug-resistant tuberculosis (XDR-TB) unresponsive to previous treatment, linezolid, an antibiotic used to treat severe bacterial infections, proved largely effective when added to the patients' ongoing TB treatment regimen.

19 Oct 2012

Companionship can reduce nerve-related pain

Companionship has the potential to reduce pain linked to nerve damage, according to a new study.

16 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

Anesthetic-loaded liposomes can delay onset of neuropathic pain

Using tiny spheres filled with an anesthetic derived from a shellfish toxin, researchers at Boston Children's Hospital and the Massachusetts Institute of Technology have developed a way to delay the rise of neuropathic pain, a chronic form of pain that arises from flawed signals transmitted by damaged nerves.

10 Oct 2012

Neuropathy News and Research

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Results of Halaven Phase III study in metastatic breast cancer presented at 2012 CTRC-AACR SABCS

Scientists identify underlying genetic cause for rare motor neurone disorder

Ultrasound applied to fingertips can stimulate sensory pathways leading to the brain

DARA BioSciences submits KRN5500 Orphan Drug Application with FDA

FDA clears NeuroMetrix’s SENSUS Pain Management System

UCB to sponsor key sets of VIMPAT C-V data at 66th American Epilepsy Society annual meeting

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Ankle repair recovery predictors identified

Top-line results from Pfizer's pregabalin CR formulation Phase 3 study on fibromyalgia

New €6 million European project to address complications associated with diabetes

Adding bortezomib ‘boosts acute myeloid leukemia chemotherapy response’

Diabetic foot complication risk highlighted in men

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Nabilone shows promise in treating diabetic neuropathy

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Linezolid proves effective in treating drug-resistant TB

Companionship can reduce nerve-related pain

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Anesthetic-loaded liposomes can delay onset of neuropathic pain

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News